Literature DB >> 17650055

Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.

Peter J Weiden1, Peter F Buckley.   

Abstract

One of the great challenges of long-term treatment of schizophrenia and related disorders is minimizing the medical or psychological burden from persistent side effects. Because of the differences in side effect profiles between the newer and older antipsychotic medications, and distinct differences among the newer agents themselves, the spectrum of side effects associated with antipsychotic therapy has changed tremendously. The authors review changing from one antipsychotic to another ("switching") as a potential treatment strategy for reducing the overall side effect burden of antipsychotic therapy. This review identifies 6 steps to the evaluation of switching antipsychotics because of side effects: (1) Establish a causal attribution that the clinical problem is an adverse effect of the antipsychotic medication; (2) Understand the course of the side effect, especially regarding present and future risks for the individual patient receiving the antipsychotic treatment; (3) Understand the potential risks and benefits of other side effect interventions that do not require switching the antipsychotic; (4) Be aware of the side effect profiles of other possible antipsychotics, with an understanding of the potential effectiveness of changing (switching) to another antipsychotic for this side effect; (5) Calculate the side effect risks of switching antipsychotics; (6) Calculate the efficacy risks of switching antipsychotics. The authors explain how to evaluate the specific side effect in the context of the current medication and the overall management of the patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17650055

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  A roadmap to key pharmacologic principles in using antipsychotics.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  [Adherence to psychopharmacological treatment: Psychotherapeutic strategies to enhance adherence].

Authors:  R Lencer; D Korn
Journal:  Nervenarzt       Date:  2015-05       Impact factor: 1.214

3.  [Computer-assisted treatment pathway for schizophrenia. Development and initial experiences].

Authors:  G Juckel; K Stahl; C Norra
Journal:  Nervenarzt       Date:  2015-01       Impact factor: 1.214

4.  Consumers' questions about antipsychotic medication: revealing safety concerns and the silent voices of young men.

Authors:  Rianne A Weersink; Katja Taxis; Treasure M McGuire; Mieke L van Driel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-12-30       Impact factor: 4.328

Review 5.  [Long-term treatment of schizophrenia spectrum disorders: focus on pharmacotherapy].

Authors:  L Deutschenbaur; M Lambert; M Walter; D Naber; C G Huber
Journal:  Nervenarzt       Date:  2014-03       Impact factor: 1.214

Review 6.  Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.

Authors:  Mehrul Hasnain; W Victor R Vieweg; Sonja K Fredrickson
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

Review 7.  Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder.

Authors:  Lewis Warrington; Ilise Lombardo; Antony Loebel; Kathleen Ice
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects.

Authors:  Peter M Haddad; W Wolfgang Fleischhacker; Joseph Peuskens; Roberto Cavallaro; Michael Ej Lean; Margarita Morozova; Gavin Reynolds; Jean-Michel Azorin; Pierre Thomas; Hans-Jürgen Möller
Journal:  Ther Adv Psychopharmacol       Date:  2014-02

9.  Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

Authors:  Leslie Citrome; Peter J Weiden; Joseph P McEvoy; Christoph U Correll; Josephine Cucchiaro; Jay Hsu; Antony Loebel
Journal:  CNS Spectr       Date:  2013-12-16       Impact factor: 3.790

10.  Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.

Authors:  Jihyung Hong; Diego Novick; Roberto Brugnoli; Jamie Karagianis; Martin Dossenbach; Josep Maria Haro
Journal:  BMC Psychiatry       Date:  2012-12-04       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.